HeartSciences (NASDAQ:HSCS) Releases Earnings Results, Beats Expectations By $0.21 EPS

HeartSciences (NASDAQ:HSCS) posted its earnings results on Monday. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.21, Zacks reports.

HeartSciences Stock Performance

HSCS opened at $2.66 on Tuesday. HeartSciences has a fifty-two week low of $2.01 and a fifty-two week high of $6.47. The company has a market capitalization of $8.46 million, a P/E ratio of -0.39 and a beta of 2.53. The stock has a fifty day moving average of $3.01 and a 200-day moving average of $3.06.

Analyst Upgrades and Downgrades

HSCS has been the topic of a number of research reports. Ascendiant Capital Markets upped their price target on shares of HeartSciences from $9.00 to $9.20 and gave the company a “buy” rating in a research note on Monday, December 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of HeartSciences in a report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $9.20.

Hedge Funds Weigh In On HeartSciences

An institutional investor recently bought a new position in HeartSciences stock. Geode Capital Management LLC acquired a new stake in HeartSciences Inc. (NASDAQ:HSCS) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned 0.51% of HeartSciences as of its most recent SEC filing. 17.24% of the stock is owned by hedge funds and other institutional investors.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.